Market Cap 7.47B
Revenue (ttm) 4.05B
Net Income (ttm) 22.20M
EPS (ttm) N/A
PE Ratio 14.59
Forward PE 16.09
Profit Margin 0.55%
Debt to Equity Ratio 0.65
Volume 1,012,223
Avg Vol 1,200,816
Day's Range N/A - N/A
Shares Out 51.14M
Stochastic %K 25%
Beta 1.45
Analysts Sell
Price Target $178.87

Latest News on CRL

Charles River Introduces Global Biotech Incubator Program

Dec 5, 2024, 8:00 AM EST - 4 months ago

Charles River Introduces Global Biotech Incubator Program


Charles River Laboratories Announces Third-Quarter 2024 Results

Nov 6, 2024, 7:00 AM EST - 5 months ago

Charles River Laboratories Announces Third-Quarter 2024 Results


Charles River to Perform Plasmid Manufacturing for AAVantgarde

Jul 8, 2024, 8:00 AM EDT - 9 months ago

Charles River to Perform Plasmid Manufacturing for AAVantgarde


A.I. Impact On Biopharma: LLY, AMGN, TMO, CRL

Jun 14, 2024, 1:27 PM EDT - 10 months ago

A.I. Impact On Biopharma: LLY, AMGN, TMO, CRL

LLY AMGN TMO